The stock of ZyVersa Therapeutics Inc (NASDAQ: ZVSA) has decreased by -9.60 when compared to last closing price of 1.25.Despite this, the company has seen a loss of -25.66% in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.
Is It Worth Investing in ZyVersa Therapeutics Inc (NASDAQ: ZVSA) Right Now?
ZVSA has 36-month beta value of 0.52. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZVSA is 1.07M, and currently, short sellers hold a 4.25% ratio of that float. The average trading volume of ZVSA on November 15, 2024 was 1.18M shares.
ZVSA’s Market Performance
ZVSA’s stock has seen a -25.66% decrease for the week, with a -50.00% drop in the past month and a -59.93% fall in the past quarter. The volatility ratio for the week is 16.04%, and the volatility levels for the past 30 days are at 14.09% for ZyVersa Therapeutics Inc The simple moving average for the past 20 days is -38.81% for ZVSA’s stock, with a -75.35% simple moving average for the past 200 days.
ZVSA Trading at -47.22% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.33% of loss for the given period.
Volatility was left at 14.09%, however, over the last 30 days, the volatility rate increased by 16.04%, as shares sank -50.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -59.64% lower at present.
During the last 5 trading sessions, ZVSA fell by -25.66%, which changed the moving average for the period of 200-days by -80.18% in comparison to the 20-day moving average, which settled at $1.8466. In addition, ZyVersa Therapeutics Inc saw -87.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ZVSA
Current profitability levels for the company are sitting at:
- -145960.12 for the present operating margin
- -0.0 for the gross margin
The net margin for ZyVersa Therapeutics Inc stands at -155140.06. The total capital return value is set at -0.29. Equity return is now at value -152.23, with -84.85 for asset returns.
Currently, EBITDA for the company is -107.74 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of -7801.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.06.
Conclusion
To put it simply, ZyVersa Therapeutics Inc (ZVSA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
